Symbol | Exchange | Currency |
|---|
Iterum Therapeutics plc (NASDAQ: ITRM) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid.Sulopenem is under review as...
DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Neutral | Strong Buy | Buy |
| Technical Indicators | Neutral | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
| Summary | Sell | Strong Sell | Sell | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,429.41 | 2,437.30 | 2,400.00 | +27.19 | +1.13% | 555.46K | NASDAQ | |||
| 331.79 | 332.92 | 327.68 | +2.13 | +0.65% | 6.37M | NASDAQ | |||
| 55.45 | 63.01 | 53.43 | -3.81 | -6.43% | 136.79M | NYSE | |||
| 13.76 | 13.96 | 11.51 | +2.36 | +20.70% | 206.78M | NASDAQ | |||
| 9.20 | 10.87 | 8.08 | +2.9300 | +46.73% | 241.29M | NASDAQ | |||
| 200.00 | 218.03 | 197.00 | -13.82 | -6.46% | 3.49M | NYSE | |||
| 222.79 | 224.99 | 218.77 | -6.50 | -2.83% | 3.09M | NASDAQ | |||
| 46.59 | 46.72 | 45.08 | -0.32 | -0.68% | 29.40M | NYSE | |||
| 20.81 | 21.14 | 20.37 | +0.54 | +2.66% | 21.47M | NYSE | |||
| 6.48 | 6.57 | 6.40 | +0.06 | +0.93% | 8.86M | NYSE | |||
| 11.28 | 11.91 | 10.77 | -0.500 | -4.24% | 20.87M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 25.50 | 25.54 | 24.51 | +0.13 | +0.51% | 24.93M | NYSE | |||
| 15.94 | 16.35 | 15.66 | -0.24 | -1.48% | 2.71M | NYSE | |||
| 1.295 | 1.36 | 1.26 | -0.0650 | -4.78% | 7.77M | NYSE |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
